Last reviewed · How we verify

NCT03473847

Repeatability, Reproducibility and Comparison of Cirrus OCT, RTVue OCT, MS-39 OCT, and Insight 100 VHFDU

Suspended NA Last updated 26 April 2022
What this trial tests

NA trial testing ArcScan Insight 100 very high-frequency digital ultrasound in Corneal Thickness Measurement in 242 participants. Suspended.

Timeline
1 September 2022
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorLondon Vision Clinic
PhaseNA
StatusSuspended
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment242
Start date1 September 2022
Primary completion1 December 2023
Estimated completion1 December 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

London Vision Clinic

Who can join

Adults 21 to 70, any sex, with Corneal Thickness Measurement or Epithelial Thickness Measurement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the repeatability and reproducibility of corneal, epithelial, and LASIK flap thickness using the Carl Zeiss Meditec Cirrus HD OCT 5000, Optovue RTVue OCT, CSO MS-39 OCT, and ArcScan Insight 100 very high-frequency digital ultrasound arc-scanner.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ArcScan Insight 100 very high-frequency digital ultrasound

Trials testing the same drug.

Other London Vision Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing